Company / Capital Expenditures
Amneal Pharmaceuticals, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$70.1M
FY2025
5-year range
$46.4M / $70.1M
FY2021-FY2025
Trend
+34.9%
vs FY2024
Sector context
#23 of 194
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s capital expenditures of $70M is higher than 88% of companies in the Health Care sector (FY2025). Capital Expenditures has increased for 3 consecutive years, from $46M in FY2022 to $70M in FY2025.
Based on SEC 10-K filings.
$70M in FY2025 with a 5-year CAGR of -3.4%. Top quartile in the Health Care sector.
Improved from $48M to $70M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +14.7%
- 5-Year CAGR
- -3.4%
- 10-Year CAGR
- -
Sector benchmark
-40.4% below sector average
Key checks
Key Insights
- Amneal Pharmaceuticals, Inc.'s capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of -3.4%, indicating a declining trend.
- In FY2025, capital expenditures increased 34.9% year-over-year.
- Ranks #23 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $70.1M | +34.9% |
| FY2024 | $51.9M | +8.8% |
| FY2023 | $47.7M | +2.8% |
| FY2022 | $46.4M | -1.6% |
| FY2021 | $47.2M | -43.2% |
| FY2020 | $83.1M | -12.3% |
| FY2019 | $94.8M | -22.8% |
| FY2018 | $122.8M | +29.5% |
| FY2017 | $94.8M | -22.8% |
| FY2016 | $122.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026